A vital branch of our Acute Care Department, the Emergency Department Clinical Research Team deliver national and international multi-centre studies in Emergency Medicine and trauma related specialities, working to advance the care that we give to our patients.
The team also work closely with colleagues across the Trust and beyond to develop new and innovative research ideas that test new treatments especially in the fields of major trauma and emergency medicine.
Please speak to the person treating you to find out if there is a research study that may be able to help you.
CRYOSTAT-2: A multi-centre, randomised, controlled trial evaluating the effects of early high-dose cryoprecipitate in adult patients with major trauma haemorrhage requiring major haemorrhage protocol (MHP) activation
Every year in the UK, trauma (e.g. car accidents, stabbings) kills 12,500 people, with most of those who die under the age of 45. For the same age group that is more than cancer, HIV/AIDS and heart disease combined. One of the most common causes of death in trauma patients is uncontrolled bleeding. At present, standard treatment for severe bleeding involves rapid infusion of red blood cells and blood components e.g. plasma and platelets in large volumes. Until recently one out of every two people who received a massive blood transfusion (more than 10 pints) would die from their injuries.
Two important studies involving bleeding trauma patients have been conducted in the last five years showing that early intervention is more effective after injury and may help save lives. Patients who have severe bleeding after injury develop a problem with their clotting system which means that they tend to bleed more. One of the main problems is due to low levels of fibrinogen, a clotting protein normally circulating in the bloodstream. Fibrinogen acts as the ‘glue’ which holds a blood clot together and at low levels, blood clots don’t form properly and bleeding can continue. Cryoprecipitate is a frozen blood component prepared from plasma and rich in fibrinogen. By transfusing cryoprecipitate early to replace fibrinogen levels in bleeding trauma patients we believe blood clots will be more stable and reduce bleeding.
We propose to undertake a large research study, called a randomised controlled trial where patients are randomly divided into two groups and treatments are compared: A) standard treatment with normal blood transfusions B) early cryoprecipitate + standard treatment with normal blood transfusions, to see if cryoprecipitate can improve survival in trauma patients with severe bleeding.
In UK hospitals, results from a large study across 22 centres show that cryoprecipitate is given on average three hours after injury. We think this is too late and want to give a high dose of cryoprecipitate within 90 minutes of a bleeding trauma patient’s admission to hospital.
This study will determine whether or not giving cryoprecipitate treatment reduces death rates. Trauma patients with severe bleeding who are taken to any Major Trauma Centre across the country will be eligible to enter the trial. The results of this study will have the potential to influence the way doctors and nurses all over the world treat trauma patients.
Principal Investigator: Dr Edd Carlton
Planned End Date: 30/12/2021
Local Ref: 3971
UK REBOA Study
In the UK around 5800 people die annually after being severely injured. One reason these patients die is because they have suffered from massive internal bleeding. If a way was found to stop this bleeding, lives could be saved.
A new treatment has been developed that could help – it is called “REBOA” (Resuscitative Endovascular Balloon Occlusion of the Aorta). REBOA involves doctors inserting a small balloon directly into the patient’s main artery and inflating it. The balloon then blocks the artery, temporarily stopping the blood flow. Stopping the blood flow in this way gives doctors time to operate. It also helps to keep blood circulating to the brain and heart. However, the parts of the body below the balloon are cut off from the normal blood flow and this may result in short- or longer-term problems.
REBOA has not been widely used because it is new, complicated to learn and we are not certain how safe and effective it is. Only three studies have been published comparing the results of patients who have received REBOA against those who did not, and results are conflicting –two studies showed REBOA was better, the other that it was worse.
In England, severely injured patients are treated in Major Trauma Centres. One Major Trauma Centre in London has now introduced REBOA and many other UK hospitals are also interested in using this technique. It is therefore important that we try to evaluate whether it is better or worse to use REBOA before it is adopted more widely into the NHS.
The aim of this study is to establish, via a randomised controlled trial, the clinical and cost-effectiveness of standard major trauma centre treatment plus REBOA, compared with standard major trauma centre treatment alone, for the management of life-threatening torso haemorrhage in UK major trauma centres.
Principal Investigator: Dr Julian Thompson
Planned End Date: 31/03/2023
Local Ref: 4237
Wound Healing In Surgery for Trauma (WHIST)
WHIST is a large randomised clinical trial comparing negative pressure wound therapy (NPWT) with standard dressings for patients with surgical wounds associated with major trauma to the limb.
All adult patients sustaining major trauma, and who require surgery for their limb injuries, will be able to take part in the trial. A total of 1540 patients will take part at several hospitals in the UK. Half of the patients will receive standard wound management and the other half NPWT.
The treatment for each individual patient will be decided by chance using a computer programme. The patients will be kept under review in the hospital clinics for a minimum of 6 months, which is the usual NHS practice after such injuries. We will record any signs of infection and take a photograph to assess wound healing. We will ask the patients themselves to rate the quality of their wound healing. We will also use questionnaires to measure the patients function and quality of life at 30 days, 3 months and 6 months after the injuries.
The main analysis of the trial will investigate differences in the number of patients who develop a wound infection in the 30 days after their injuries. This will allow us to determine whether NPWT reduces the rate of infection.
Principal Investigator: Mr Andrew Riddick
Planned End Date: 30/10/2023
Local Ref: 3706
Become one of the thousands of people taking part in research every day within the NHS.
Find out more about our research and how we're working to improve patient care.